<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02351843</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00058639</org_study_id>
    <nct_id>NCT02351843</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Low Amplitude Electroconvulsive Therapy</brief_title>
  <official_title>Efficacy and Safety of Low Amplitude Electroconvulsive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the clinical feasibility of low amplitude
      electroconvulsive therapy (ECT) to reduce, and possibly eliminate the side effects of ECT by
      lowering the strength of the ECT stimulus from the conventional 800 mA to 500 mA. Low
      amplitude ECT could potentially reduce the risks associated with ECT while preserving its
      unparalleled efficacy. This novel development would remove key obstacles to allow for the
      wider adoption of ECT as a safe and effective therapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in California Verbal Learning Test-II</measure>
    <time_frame>Baseline and within 24 to 48 hours of each ECT session</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Change in Hamilton Rating Scale for Depression 24-item</measure>
    <time_frame>Baseline and within 24 to 48 hours of each ECT session</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Quick Inventory of Depressive Symptomatology Clinician Rated and Self Report</measure>
    <time_frame>Baseline and within 24 to 48 hours of each ECT session</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Brief Visuospatial Memory Test-Revised</measure>
    <time_frame>Baseline and within 24 to 48 hours of each ECT session</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Autobiographical Memory Interview Test</measure>
    <time_frame>Baseline and within 24 to 48 hours of each ECT session</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Delis Kaplan Executive Function System</measure>
    <time_frame>Baseline and within 24 to 48 hours of each ECT session</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Trail Making Test Part A</measure>
    <time_frame>Baseline and within 24 to 48 hours of each ECT session</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Grooved Pegboard test</measure>
    <time_frame>Baseline and within 24 to 48 hours of each ECT session</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>500 mA ECT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Right unilateral, ultra brief pulse ECT, with 500 mA current amplitude</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 mA ECT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Right unilateral, ultra brief pulse ECT, with 800 mA current amplitude</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MECTA Spectrum 5000Q</intervention_name>
    <arm_group_label>500 mA ECT</arm_group_label>
    <arm_group_label>800 mA ECT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects, age 18-70

          2. DSM-IV-TR diagnosis of major depressive episode in unipolar or bipolar disorder,
             confirmed by the MINI-PLUS

          3. MMSE total score &gt; 26

          4. Referred for ECT

          5. Competent to provide informed consent

          6. Able to read or comprehend English

        Exclusion Criteria:

          1. Lifetime history of schizophrenia, schizoaffective disorder, mental retardation

          2. Current neurostimulation treatment (e.g., ECT, magnetic seizure therapy, transcranial
             magnetic stimulation, vagus nerve stimulation, deep brain stimulation)

          3. Current alcohol abuse or dependence within past 6 months

          4. Current substance abuse or dependence within past 6 months

          5. History of central nervous system (CNS) disease

          6. Current diagnosis of dementia or delirium

          7. MoCA total score &lt; 26

          8. Current visual, auditory, or motor impairment that compromises ability to complete
             evaluations

          9. Patients with intracranial implants

         10. MRI contraindications: pregnancy, implanted metal, and claustrophobia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DukeUMC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2015</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

